Payment for drugs
Thomas, P.
Bmj 303(6806): 858
1991
ISSN/ISBN: 0959-8138 PMID: 1932996 Document Number: 381696
Document emailed within 1 workday
Related Documents
Reuveni, H.; Sheizaf, B.; Elhayany, A.; Sherf, M.; Limoni, Y.; Scharff, S.; Peled, R. 2002: The effect of drug co-payment policy on the purchase of prescription drugs for children with infections in the community Health Policy 62(1): 1-13Vesely, R. 2009: Adventures in reimbursement. Mass. eyes global payment solution to end fee-for-service, but some take 'been there, done that' stance to payment strategy Modern Healthcare 39(30): 6-7; 16, 1
Zachariah, R.; Van Engelgem, I.; Massaquoi, M.; Kocholla, L.; Manzi, M.; Suleh, A.; Phillips, M.; Borgdorff, M. 2008: Payment for antiretroviral drugs is associated with a higher rate of patients lost to follow-up than those offered free-of-charge therapy in Nairobi, Kenya Transactions of the Royal Society of Tropical Medicine and Hygiene 102(3): 288-293
Onwujekwe, O.; Ojukwu, J.; Shu, E.; Uzochukwu, B. 2007: Inequities in valuation of benefits, choice of drugs, and mode of payment for malaria treatment services provided by community health workers in Nigeria American Journal of Tropical Medicine and Hygiene 77(1): 16-21
Rutherford, R. 2017: Thriving Under Medicare's Newest Pay-for- Performance Program: Making Sense of the Merit-Based Incentive Payment System And the Alternative Payment Models: Part I Journal of Medical Practice Management: Mpm 32(5): 320-323
Fisher, C. 1998: Linking payment and quality. Quality measurement and prospective payment will hinge on electronic transmission of MDS data Provider 24(3): 26-27; 29-30; 33-37
Elit, L.; Cosby, J. 2006: Does shifting a physician payment system shift physician priorities? a multi-site evaluation of an alternative payment plan (APP) for gynecologic oncologists in Ontario European Journal of Gynaecological Oncology 27(4): 375-378
Wrześniok, D.; Buszman, E.; Matusiński, B. 2003: Drugs ototoxicity. Part II. Loop diuretics, nonsteroidal anti-inflammatory drugs, antineoplastic and antimalarial drugs Wiadomosci Lekarskie 56(7-8): 369-374
McGettigan, P.; Roderick, P.; Mahajan, R.; Kadam, A.; Pollock, A.M. 2015: Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs PLOS Medicine 12(5): E1001826; Discussion E1001826
Marek, J. 1985: On the non-specific antiinflammatory effects of other-than-antirheumatic drugs. Psychotropic drugs, inflammation and antiinflammatory drugs International Journal of Tissue Reactions 7(6): 475-504
Mulvany, C. 2016: An evolving DSH payment Healthcare Financial Management: Journal of the Healthcare Financial Management Association 70(6): 34-37
BeSaw, L. 1997: Payment hassles Texas Medicine 93(1): 36-39
Samorodin, C.; Burnett, J.W. 1994: Pearls on payment Cutis 53(5): 231
Smith, W.J. 1985: A new payment schedule? Rhode Island Medical Journal 68(12): 539
Martz, E.W. 1994: Progress and payment Delaware Medical Journal 66(3): 187-188
Punch, L. 1983: Payment changes pit M.D.s vs. hospitals Modern Healthcare 13(5): 38 40
Gosfield, A.G. 2013: Understanding the new payment models Medical Economics 90(15): 44-46; 49
Hoaken, P.C. 1970: Payment for chiropractic services Canadian Medical Association Journal 103(4): 396
Ishikawa, K.B. 2006: Chemotherapy and DPC, prospective payment Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(2): 159-163
Moynihan, J.J. 1996: EDIBANX: a new Edi payment resource Healthcare Financial Management: Journal of the Healthcare Financial Management Association 50(6): 96